Sciele takeover nets veteran reps

Share this article:
With its acquisition of Sciele Pharma, Osaka, Japan-based Shionogi & Co. will gain immediate entry into the US pharmaceutical market and inherit 720 seasoned sales reps. 

Under the terms of the agreement, Shionogi will acquire Sciele for $1.1 billion. Upon approval, Sciele will become a wholly owned subsidiary and will continue operating from its Atlanta headquarters as a standalone unit. The acquisition is not expected to result in the reduction of Sciele employees.

Shionogi will acquire five products in Phase II development or later by the end of 2009. The acquisition is expected to be completed by the fourth quarter of this year.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters